PRL and cancer: KEGG analysis identified 28 enriched pathways, including “transcriptional misregulation in cancer” (p = 0.0002), “metabolic pathways” (p = 0.0003), “endometrial cancer” (p = 0.0007), “prolactin signaling pathway” (p = 0.0012), and “MAPK signaling pathway” (p = 0.0110) (Fig. 2C).